NeoGenomics, Inc. (NASDAQ: NEO) announced the departure of CEO Mark Mallon, effective immediately, and appointed Lynn Tetrault as Executive Chair. The company expects first-quarter 2022 revenue below prior guidance of $118-$120 million and an EBITDA loss greater than anticipated, mainly due to increased Clinical Services costs. Guidance for 2022 has been withdrawn. Tetrault expressed commitment to improving performance and emphasized the leadership's continuity during the CEO search. Full Q1 results will be reported on April 27, 2022.

NeoGenomics (NASDAQ: NEO) announced new data supporting its RaDaR liquid biopsy test for early-stage non-small cell lung cancer (NSCLC), published in the Annals of Oncology. The LUCID study found that detectable ctDNA post-treatment was highly predictive of cancer recurrence, with specificity and positive predictive value at 100%. Notably, ctDNA detection preceded clinical recurrence by a median of 212.5 days. The study reinforces RaDaR's potential to improve patient outcomes by identifying those needing further treatment.

NeoGenomics, Inc. (NASDAQ: NEO) announced participation in key investor conferences. Senior management will engage in meetings and a fireside chat at the Raymond James 43rd Annual Institutional Investors Conference in Orlando on March 7, 2022, at 2:15 PM ET, and at Cowen's 42nd Annual Health Care Conference on March 9, 2022, at 1:30 PM ET. Both events will be webcast live on the company's website. NeoGenomics specializes in cancer genetics testing and offers extensive services to support oncology diagnosis and treatment.

NeoGenomics reported a 9% year-over-year increase in consolidated revenue for 2021, reaching $484 million. Excluding COVID-19 PCR testing, revenue rose 16%. The fourth quarter's revenue remained flat at $126 million, with a 3% decline in Clinical Services revenue. Gross profit fell 21.2% to $45.3 million, attributed to higher costs and the end of PCR testing. Full-year net loss was $8 million, a notable shift from previous profits. The company anticipates 2022 revenue of $530-$550 million but projects losses of $133-$118 million.

NeoGenomics, Inc. (NASDAQ: NEO) has appointed Dr. Shashikant Kulkarni as Executive Vice President for Research & Development and Chief Scientific Officer, effective March 7, 2022. Dr. Kulkarni, previously at Baylor Genetics, brings extensive experience in cancer genomics and has served on several regulatory panels. He aims to enhance NeoGenomics' diagnostic capabilities across the cancer care continuum. CEO Mark Mallon highlights Dr. Kulkarni's expertise as pivotal for innovation in precision medicine.

NeoGenomics has announced successful clinical validation of its RaDaR liquid biopsy test for head and neck squamous cell carcinoma (HNSCC), demonstrating 100% specificity and sensitivity. The data published in the British Journal of Cancer showed that all 17 patients tested had detectable circulating tumor DNA (ctDNA) before surgery, and 100% of patients who experienced recurrence were identified with lead times of 108 to 253 days. This highlights the potential of RaDaR for early intervention and personalized therapy planning in cancer treatment.

NeoGenomics, Inc. (NASDAQ: NEO), a leader in cancer-focused genetic testing, announced participation in several institutional investor conferences on February 17, 2022. The management will engage in investor meetings and fireside chats at SVB Leerink's and BTIG's conferences, both available via live webcast on their website. NeoGenomics, headquartered in Fort Myers, FL, operates accredited laboratories across the U.S. and internationally, providing extensive oncology testing services to support cancer diagnosis and treatment.

NeoGenomics, Inc. (NASDAQ:NEO) announced plans to release its fourth quarter and full year 2021 financial results on February 23, 2022. A webcast and conference call are scheduled for 8:30 AM EDT on the same day to discuss the results. Interested parties can access the call by dialing (888) 506-0062 domestically or (973) 528-0011 internationally. NeoGenomics specializes in cancer genetics testing and provides services for clinical trials, operating facilities in multiple locations, including the US and Europe. The company is committed to data protection and utilizing advanced technology.

NeoGenomics, Inc. (NASDAQ:NEO) has announced a strategic partnership with the Biomarker Collaborative to enhance support for cancer patients with specific biomarkers. This initiative enables patients who test positive for lung cancer biomarkers to access a dedicated resource page, offering education and connections to support groups. CEO Mark Mallon emphasized the importance of this partnership in improving patient care and outcomes. Through this collaboration, both patients and oncologists will have clearer insights into relevant biomarker groups crucial for treatment.